Alembic Pharmaceuticals Limited

Equities

APLLTD

INE901L01018

Pharmaceuticals

Market Closed - NSE India S.E. 05:13:47 10/05/2024 pm IST 5-day change 1st Jan Change
975.6 INR -2.57% Intraday chart for Alembic Pharmaceuticals Limited -4.75% +28.47%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Transcript : Alembic Pharmaceuticals Limited, Q4 2024 Earnings Call, May 09, 2024
Alembic Pharmaceuticals' Consolidated Net Profit Jumps in Fiscal Q4 MT
India's Alembic Pharma posts higher Q4 profit on strong N.America sales RE
Alembic Pharmaceuticals Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2024 CI
Alembic Pharmaceuticals Limited Reports Earnings Results for the Full Year Ended March 31, 2024 CI
Alembic Pharmaceuticals Limited Recommends Dividend for the Financial Year 2023-24 CI
Alembic Pharmaceuticals Limited Receives Various US Food & Drug Administration (Tentative or Final) Product Approvals CI
Alembic Pharmaceuticals Limited Receives an Order from the Office of Deputy Commissioner, DGSTO-02, Bengaluru, Karnataka CI
Alembic Pharmaceuticals Limited Receives Order from the Office of Deputy Commissioner (ST), Guwahati, Assam CI
Alembic Pharmaceuticals Board to Consider Dividend for Fiscal 2024; Shares Drop 3% MT
Alembic Pharmaceuticals Limited Received 3 Assessment Orders from the Office of Assistant Commissioner (ST), Andhra Pradesh CI
Alembic Pharmaceuticals Appoints Manish Kejriwal as Independent Director CI
Alembic Pharmaceuticals Gets US FDA Tentative Nod for Generic Breast Cancer Treatment MT
Alembic Pharmaceuticals Limited Receives One US Food & Drug Administration Product Approval CI
Alembic Pharmaceuticals Limited Announces Board Cessations CI
Alembic Pharmaceuticals Limited Receives Order from Commission of Customs, Mumbai Zone- III CI
Alembic Pharmaceuticals' Oncology Plant in Gujarat, India Gets One Observation from US FDA MT
Alembic Pharmaceuticals Limited Announces United States Food and Drug Administration Conducted an Inspection At Oncology Formulation Facility At Panelav CI
Crisil Keeps AA+ Rating on Alembic Pharmaceuticals' Bank Loans with Stable Outlook MT
Indian shares seen muted tracking broader Asian equities RE
Alembic Pharmaceuticals Fully Resumes Operations at Manufacturing Unit in South Sikkim, India MT
Alembic Pharmaceuticals' Consolidated Net Profit Jumps in Fiscal Q3; EPS Tops Estimates MT
Alembic Pharmaceuticals' Consolidated Profit Climbs in Fiscal Q3, EPS Beats Estimates MT
Transcript : Alembic Pharmaceuticals Limited, Q3 2024 Earnings Call, Feb 05, 2024
India's Alembic Pharma beats Q3 profit view on strong domestic, US sales RE
Chart Alembic Pharmaceuticals Limited
More charts
Alembic Pharmaceuticals Limited is an India-based pharmaceutical company. The Company is involved in manufacturing and marketing India Formulations, International Generics, and Active Pharmaceutical Ingredients (API). It delivers a diverse and expanding range of generics across chronic segments. Its therapies include Dermatology, Anti-Infective, Cold & Cough, Gastrology, Cardiology, Anti-Diabetic, Ophthalmology, Nephro/Uro, Animal Health, Orthopaedic and Gynaecology. Products under International Generics are manufactured across its facilities in Panelav, Karkhadi and Jarod in Gujarat. It has research and development facilities in Vadodara (Gujarat), Hyderabad (Telangana), and New Jersey (United States). Its APIs are manufactured at its three plants in Panelav and Karkhadi in Gujarat. The manufacturing facility in Sikkim is for manufacturing its India Formulations. Its subsidiaries include Alembic Pharmaceuticals Inc., Alembic Global Holding SA and others.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
13
Last Close Price
975.6 INR
Average target price
959.3 INR
Spread / Average Target
-1.67%
Consensus
  1. Stock Market
  2. Equities
  3. APLLTD Stock
  4. News Alembic Pharmaceuticals Limited
  5. Alembic Pharmaceuticals Says Operations at South Sikkim Plant Disrupted by Flash Floods
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW